Lynn is a registered patent agent who focuses on patent prosecution and IP strategy in the life sciences and pharmaceuticals. She assists companies at all stages of development, as well as private and public institutions, in the growth and maintenance of their IP portfolios.

Lynn has patent prosecution, management, and strategy experience in a broad range of technologies, including vaccines, immuno-oncology, protein- and gene-based therapies, antibodies, cell therapies, gene editing, biomarkers, infectious disease, recombinant nucleic acids, gene therapy, and synthetic biology. She also has extensive experience in the areas of freedom-to-operate analysis, patentability assessment, and IP due diligence and has assisted in inter partes reviews. Before joining Mintz, Lynn was a patent agent with a national law firm where she handled domestic and international patent prosecution for a wide variety of clients.

Lynn has many years of laboratory research experience in the fields of immunology, neuroscience, virology, molecular biology, and gene therapy. She earned her doctorate degree at the University of Rochester, where she studied neurotrophin-induced cell survival mechanisms in neuronal and non-neuronal cell types for the purposes of understanding these mechanisms in the context of HIV and cancer. Following completion of her PhD, Lynn performed her postdoctoral work in gene therapy where she developed a method for cell-specific targeting of plasmid DNA to alveolar epithelial type I cells.

Lynn has published papers on gene therapy, HIV, cancer, and neurological disease in a number of publications, including the Journal of Neuroinflammation, Experimental Hematology, Molecular and Cellular Neuroscience, and the Journal of Immunology.